David Friedman

In a report published Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Relypsa (NASDAQ: RLYP) with an Overweight rating and $57.00 price target. In the report, Morgan Stanley noted, “We are OW Relypsa as we believe patiromer has $850+mn revenue potential in hyperK+. Patiromer...

In a report published Thursday, Morgan Stanley analyst David Friedman reiterated an Equal-Weight rating and $9.00 price target on InterMune (NASDAQ: ITMN). In the report, Morgan Stanley noted, “2Q sales of $14.4mn were above our $12.25mn estimate. Intermune increased the sales guidance range to...

In a report published on Monday, Morgan Stanley analyst David Friedman initiated coverage on Portola Pharmaceuticals (NASDAQ: PTLA) with a rating of Overweight and a price target of $32. In the report, Morgan Stanley stated, "We see each of these drugs as potentially fulfilling a serious unmet...

In a report published Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with an Overweight rating and $35.00 price target. In the report, Morgan Stanley noted, “We view Alnylam as the leader in RNAi drug development. The components of...

In a report published on Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with an Overweight rating and a price target of $35. In the report, Morgan Stanley stated, "We view Alnylam as the leader in RNAi drug development. The components...

In a report published on Tuesday, Morgan Stanley analyst David Friedman downgraded XenoPort (NASDAQ: XNPT) from Equal-Weight to Underweight and lowered the price target on the company from $3 to $2. In the report, Morgan Stanley stated, "We are downgrading to UW post the recent Ph 3 AP failure...

In a report published on Tuesday, Morgan Stanley analyst David Friedman downgraded Lexicon Pharmaceuticals (NASDAQ: LXRX) from Equal-Weight to Underweight and lowered the price target on the company from $2 to $1.50. In the report, Morgan Stanley noted, "...we are updating our assumptions for...